Redsense Medical fortsätter att växa trots valutamotvind, med en stark Q3-förbättring både i omsättn...
* Encouraging ACV growth and margins * Small sales revisions, but '26e-'27e EBIT up 29-28% on lower ...
Top Picks comments on a significant development that fundamentally changes one of our investment the...
Redeye comments on the new orphan drug designation for the treatment of Osteogenesis Imperfecta from...
Redeye provides a research update following the recently published Q3 report from Lipum.
Redeye returns with an updated view of Egetis Therapeutics following the Q3 report and the recent Re...
* European Commission drafts proposal for non-renewal of Selektope * Limited impact on near-term est...
European Commission draft, suggests a non-renewal for Selektope under EU BPR, which now seems as the...
Redeye updates its estimates and fair value range following Xplora’s Q3 report, which surprised posi...
Redeye visited Cheffelo’s Mölnlycke facility, where Linas Matkasse’s meal kits are produced.
Xplora reported strong demand for its products and subscriptions in the Q3 report, and it reported g...
Redeye comments on Polygiene's CEO shift that was announced today.
* NetApp +5% on EPS beat, but reiterated low growth revenue guidance * Dell +3%, storage revenues de...
Redeye comments on Iconovo’s announcement of a directed share issue and a fully guaranteed rights is...
Redeye notes that Xplora’s third-quarter report marks a distinct inflection in profitability, with a...
Redeye provides an updated valuation of Alligator as the subscription price in the rights issue, SEK...
Xplora's gross profit came in stronger than expected at NOK 263m, 4% higher than consensus, driven b...
Redeye comments on Surgical Science dropping an absolute bomb of a press release.
Redeye initiates coverage of Ferroamp, a greentech company offering a modular hardware and software ...
* ~SEK 26m defence order announced earlier today * Backlog of ~SEK 390m * Provides additional visibi...
